HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $13.32, but opened at $13.99. HUTCHMED shares last traded at $14.21, with a volume of 21,761 shares traded.
Analyst Ratings Changes
Separately, StockNews.com lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
Get Our Latest Report on HCM
HUTCHMED Trading Up 6.6 %
The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The business has a fifty day moving average price of $15.88 and a two-hundred day moving average price of $17.66.
Institutional Trading of HUTCHMED
Hedge funds have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio acquired a new position in HUTCHMED in the 3rd quarter valued at approximately $35,000. Blue Trust Inc. increased its stake in shares of HUTCHMED by 638.2% in the third quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock worth $69,000 after acquiring an additional 3,057 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of HUTCHMED by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company's stock worth $117,000 after acquiring an additional 2,321 shares in the last quarter. Rhumbline Advisers boosted its position in HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock valued at $129,000 after purchasing an additional 564 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in HUTCHMED in the second quarter valued at about $213,000. 8.82% of the stock is owned by hedge funds and other institutional investors.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
